• Markets
    • icon
  • Companies
PAA · ASX

Pharmaust Limited (ASX:PAA)

AU$0.094

 0.0 (0.0%)
ASX:Live
01/12/2023 04:10:47 PM
Near Resistance HALO Price Momentum HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PAA Overview

PAA Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About PAA

Website

Pharmaust Limited

Telephone

61.8.9202.6814

Address

Suite 116 1 Kyle Way Claremont, Western Australia (WA) 6010

Description

PharmAust Ltd. is a pharmaceutical company, which provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. It operates through two segments: Corporate and Pharmaceutical. The Corporate segment covers all the corporate overhead expenses. The Pharmaceutical segment provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company was founded on December 2003 and is headquartered in Claremont, Australia.

PAA Price Chart

Key Stats

Market Cap

AU$32.44M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.06 - 0.12

Trade Value (12mth)

AU$6,191.00

1 week

9.3%

1 month

27.03%

YTD

44.62%

1 year

34.29%

All time high

4.73999

Key Fundamentals

EPS 3 yr Growth

321.700%

EBITDA Margin

-116.70%

Operating Cashflow

-$2m

Free Cash Flow Return

-22.90%

ROIC

-90.90%

Interest Coverage

-40.30

Quick Ratio

2.20

Other Data

Shares on Issue (Fully Dilluted)

321m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PAA Announcements

Latest Announcements

Date Announcements

31 October 22

Appendix 4C and Quarterly Update

×

Appendix 4C and Quarterly Update

31 May 13

PharmAust / Pitney Investor Presentation

×

PharmAust / Pitney Investor Presentation

31 March 22

Notification of cessation of securities - PAA

×

Notification of cessation of securities - PAA

31 March 10

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

31 July 23

Appendix 4C and Quarterly Update

×

Appendix 4C and Quarterly Update

31 January 22

Appendix 4C and Quarterly Update

×

Appendix 4C and Quarterly Update

31 August 23

Appendix 4E & Full Year Statutory Accounts

×

Appendix 4E & Full Year Statutory Accounts

31 August 23

Appendix 4G & Corporate Governance Statement

×

Appendix 4G & Corporate Governance Statement

30 September 22

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

30 October 23

Appendix 4C and Quarterly Update

×

Appendix 4C and Quarterly Update

30 October 09

Annual Report to shareholders

×

Annual Report to shareholders

30 October 09

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

30 May 22

Fiona Milner appointed Epichem General Manager

×

Fiona Milner appointed Epichem General Manager

30 March 23

MND Trial Completes Enrolment of Cohort 2

×

MND Trial Completes Enrolment of Cohort 2

30 June 23

General Meeting - Chairman Script

×

General Meeting - Chairman Script

30 June 23

Trading Halt

×

Trading Halt

30 June 23

Results of General Meeting

×

Results of General Meeting

30 June 22

Notification of cessation of securities - PAA

×

Notification of cessation of securities - PAA

30 January 23

Appendix 4C and Quarterly Update

×

Appendix 4C and Quarterly Update

30 August 17

PharmAust Investor Presentation

×

PharmAust Investor Presentation

29 September 23

Notification of expiry of quoted options

×

Notification of expiry of quoted options

29 September 08

Annual Report to shareholders

×

Annual Report to shareholders

29 October 13

PharmAust AGM 2013 Presentation

×

PharmAust AGM 2013 Presentation

29 October 13

Results of Annual General Meeting

×

Results of Annual General Meeting

29 November 17

PharmAust AGM Presentation

×

PharmAust AGM Presentation

29 November 17

Results of Annual General Meeting

×

Results of Annual General Meeting

29 August 16

PharmAust Investor Presentation - August 2016

×

PharmAust Investor Presentation - August 2016

29 April 22

Appendix 4C and Quarterly Update

×

Appendix 4C and Quarterly Update

PAA Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.01 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.01 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 8.7 -28.6 -259.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 15.2 -67.8 -17.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -3.6 -6.2 -6.6 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.03 0.02 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.02 0.01 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.0 -17.5 -84.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 316 317 321 Lock Lock Lock
Basic m Lock Lock Lock Lock 316 317 321 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 2 3 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.0 58.0 -16.5 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 2 3 3 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 0 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -82.0 71.0 -315.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -36.0 -6.6 -32.9 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 136 107 133 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -2 -2 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -31.4 2.3 -35.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -116.4 -72.0 -116.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -3 -3 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -28.5 1.5 -31.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -130.3 -81.3 -128.3 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -1 -2 -6 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -1 -2 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.8 -27.7 -263.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -62.5 -50.5 -220.0 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -1 -1 -2 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 1 1 2 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -1 -1 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 20.0 -32.3 -16.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.5 -0.4 -0.6 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 3 2 3 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 11 10 6 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -2 -1 -2 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 9 8 4 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 10 9 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3.8 -11.3 -46.2 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -12.2 -16.9 -101.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -15.1 -21.8 -159.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -27.7 -28.4 -51.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -13.6 -18.1 -90.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -9.5 -14.1 -22.9 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -31.5 -27.5 -40.3 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.7 0.4 0.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -19.7 -13.2 -42.7 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 4.8 3.2 2.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.7 2.3 2.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 69.4 64.9 89.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -102.9 -114.3 -116.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 7.5 14.5 13.5 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 3.1 3.5 7.2 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.6 1.3 1.7 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 26.1 17.9 32.8 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.2 0.3 0.5 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.2 0.3 0.5 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -62.5 -50.5 -220.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -12.2 -16.9 -101.3 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -12.2 -16.9 -101.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.3 1.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -15.1 -21.8 -159.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -15.1 -21.8 -159.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 116.9 103.8 50.7 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 48.8 25.1 27.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 165.7 129.0 77.7 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 66.5 58.3 103.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 99.2 70.7 -25.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PAA Shortsell

Frequently Asked Questions

The current share price of Pharmaust Limited (PAA:ASX) is AU$0.094.
The 52-week high share price for Pharmaust Limited (PAA:ASX) is AU$0.12.
The 52-week low share price for Pharmaust Limited (PAA:ASX)? is AU$0.06.
Pharmaust Limited (PAA:ASX) does not pay a dividend.
Pharmaust Limited (PAA:ASX) does not pay a dividend.
Pharmaust Limited (PAA:ASX) has a franking level of 0%.
Pharmaust Limited (PAA:ASX) is classified in the Healthcare.
The current P/E ratio for Pharmaust Limited (PAA:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.